UNSPSC 51461507: Chelidonium majus

This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E889U5RNN (and, in top and root form, O9HP59XU7F and FLT36UCF0N), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 501481 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Ranunculanae, Order Ranunculales, Family Papaveraceae, Genus Chelidonium L. (celandine), Species Chelidonium majus L., more commonly known as CELANDINE or as here, CHELIDONIUM MAJUS.

UNSPSC 51461507 Chelidonium majus is a Commodity code capturing botanical pharmaceutical products, though recent state and local solicitation activity under this code shows minimal direct relevance to the narrow botanical scope. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a broad RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon; the RFP does not isolate Chelidonium majus or botanical therapeutics as a distinct category, instead treating them as potential line items within a comprehensive pharmaceutical supply contract. State and local health agencies, corrections departments, and municipal facilities use this code—when applicable—for specialized botanical or plant-derived pharmaceutical ingredients and finished dosage forms that may fall outside standard generic drug classifications. The MMCAP procurement exemplifies the cooperative purchasing vehicle most commonly used for pharmaceutical procurement across state and local government; repeat buyers include Minnesota's central procurement office and multistate alliances pooling purchasing volume to negotiate pricing leverage with manufacturers and wholesalers.

The code shows activity concentrated in the Upper Midwest, with MMCAP's multistate cooperative structure spanning Minnesota and Oregon as of the most recent filing. MMCAP's RFP (Solicitation S1070000015802, due March 26, 2026) represents the primary recent opportunity under this code; vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain comprehensive insurance (commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000). Awarded contracts will take effect July 1, 2026, with a two-year initial term and optional extensions. Pricing is weighted at 75 percent of the evaluation, with vendors offering flat-price, net-price (NF30, NF60, NF90), or WAC-minus structures; all products must comply with FDA requirements, current Good Manufacturing Practices (cGMP), and the Drug Supply Chain Security Act (DSCSA), and carry expiration dates of at least one year from manufacture with a minimum six-month shelf life.